Skip to main content
Erschienen in: Clinical and Experimental Medicine 2/2023

21.04.2022 | Original Article

Assessment of anti-desmoglein antibodies levels and other laboratory indexes as objective comprehensive indicators of patients with pemphigus vulgaris of different severity: a single-center retrospective study

verfasst von: Xiaoying Lin, Xiaolan Li

Erschienen in: Clinical and Experimental Medicine | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study is to assess the utility of anti-desmoglein (Dsg) antibodies levels, hematological biomarkers levels, the albumin to globulin (A/G) ratio, blood lipids levels, and lymphocyte subpopulation percentages as objective laboratory indicators of disease severity of pemphigus vulgaris (PV). A retrospective study of 187 PV patients with 256 medical records between January 2013 and December 2020. PV patients were divided into three groups by disease severity according to the pemphigus disease area index (PDAI) score: mild (0–8), moderate (9–24), and severe (≥ 25). The levels of anti-Dsg antibodies, hematological biomarkers, A/G ratio, blood lipids, and the percentage of lymphocyte subpopulations were measured. We assessed the correlations of quantitative variables by Pearson correlation (r). Multivariable linear regression was used to identify the variables associated with the disease severity of PV (PDAI score). The results show that the levels of Dsg1 (r = 0.294, P < 0.001) and Dsg3 (r = 0.206, P = 0.011), monocyte count (r = 0.210, P = 0.001), neutrophil-to-lymphocyte ratio (NLR) (r = 0.123, P = 0.049), and platelet-to-lymphocyte ratio (PLR) (r = 0.170, P = 0.006) were positively correlated with the PDAI score. However, the A/G ratio (r = − 0.399, P < 0.001), and the levels of total serum cholesterol (r = − 0.140, P = 0.026) and HDL (r = − 0.143, P = 0.023) were negatively correlated with the PDAI score. Multiple linear regression showed that the factors associated with the PDAI score were higher level of anti-Dsg1 antibody (P = 0.001), a higher NLR (P = 0.005), and a lower A/G ratio (P < 0.001). The linear regression equation was Y(PDAI) = 32.798 + 0.058X(Dsg1) + 0.846 X(NLR)−16.472 X(A/G) (R2 = 0.586). Therefore, high levels of anti-Dsg1 antibody and NLR combined with a low A/G ratio could explain the PDAI score. These findings might provide a more comprehensive and objective evaluation system for reflecting the disease severity of PV based on laboratory indicators.
Literatur
2.
Zurück zum Zitat Ujiie I, Ujiie H, Iwata H, Shimizu H. Clinical and immunological features of pemphigus relapse. Br J Dermatol. 2019;180(6):1498–505.CrossRefPubMed Ujiie I, Ujiie H, Iwata H, Shimizu H. Clinical and immunological features of pemphigus relapse. Br J Dermatol. 2019;180(6):1498–505.CrossRefPubMed
3.
Zurück zum Zitat Sibel Berksoy H, Rukiye G, Melih A. Blood mean platelet volume may be predictive for disease course in the cases with pemphigus vulgaris. Biomed Res. 2017;28(9):4223–7. Sibel Berksoy H, Rukiye G, Melih A. Blood mean platelet volume may be predictive for disease course in the cases with pemphigus vulgaris. Biomed Res. 2017;28(9):4223–7.
4.
Zurück zum Zitat Wohl Y, Dreiher J, Cohen AD. Pemphigus and dyslipidaemia: a case-control study. Br J Dermatol. 2009;161(6):1418–20.CrossRefPubMed Wohl Y, Dreiher J, Cohen AD. Pemphigus and dyslipidaemia: a case-control study. Br J Dermatol. 2009;161(6):1418–20.CrossRefPubMed
5.
Zurück zum Zitat Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58(6):1043–6.CrossRefPubMedPubMedCentral Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58(6):1043–6.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Cozzani E, Di Zenzo G, Riva S, et al. Are clinical phenotype and autoantibody profile always concordant in pemphigus? A study in a cohort of pemphigus patients. Eur J Dermatol. 2013;23(1):40–8.CrossRefPubMed Cozzani E, Di Zenzo G, Riva S, et al. Are clinical phenotype and autoantibody profile always concordant in pemphigus? A study in a cohort of pemphigus patients. Eur J Dermatol. 2013;23(1):40–8.CrossRefPubMed
7.
Zurück zum Zitat Sen BB, Rifaioglu EN, Ekiz O, Inan MU, Sen T, Sen N. Neutrophil to lymphocyte ratio as a measure of systemic inflammation in psoriasis. Cutan Ocul Toxicol. 2014;33(3):223–7.CrossRefPubMed Sen BB, Rifaioglu EN, Ekiz O, Inan MU, Sen T, Sen N. Neutrophil to lymphocyte ratio as a measure of systemic inflammation in psoriasis. Cutan Ocul Toxicol. 2014;33(3):223–7.CrossRefPubMed
8.
Zurück zum Zitat Imtiaz F, Shafique K, Mirza SS, Ayoob Z, Vart P, Rao S. Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population. Int Arch Med. 2012;5(1):2.CrossRefPubMedPubMedCentral Imtiaz F, Shafique K, Mirza SS, Ayoob Z, Vart P, Rao S. Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population. Int Arch Med. 2012;5(1):2.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Lyakhovitsky A, Dascalu J, Drousiotis T, Barzilai A, Baum S. Hematological inflammatory markers in patients with pemphigus vulgaris. Dermatology. 2021;237(6):912–20.CrossRefPubMed Lyakhovitsky A, Dascalu J, Drousiotis T, Barzilai A, Baum S. Hematological inflammatory markers in patients with pemphigus vulgaris. Dermatology. 2021;237(6):912–20.CrossRefPubMed
10.
Zurück zum Zitat Akboga MK, Canpolat U, Balci KG, et al. Increased platelet to lymphocyte ratio is related to slow coronary flow. Angiology. 2016;67(1):21–6.CrossRefPubMed Akboga MK, Canpolat U, Balci KG, et al. Increased platelet to lymphocyte ratio is related to slow coronary flow. Angiology. 2016;67(1):21–6.CrossRefPubMed
11.
Zurück zum Zitat Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des. 2011;17(1):47–58.CrossRefPubMed Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des. 2011;17(1):47–58.CrossRefPubMed
12.
Zurück zum Zitat Spinella R, Sawhney R, Jalan R. Albumin in chronic liver disease: structure, functions and therapeutic implications. Hep Int. 2016;10(1):124–32.CrossRef Spinella R, Sawhney R, Jalan R. Albumin in chronic liver disease: structure, functions and therapeutic implications. Hep Int. 2016;10(1):124–32.CrossRef
13.
Zurück zum Zitat Javanbakht MH, Djalali M, Daneshpazhooh M, et al. Evaluation of antioxidant enzyme activity and antioxidant capacity in patients with newly diagnosed pemphigus vulgaris. Clin Exp Dermatol. 2015;40(3):313–7.CrossRefPubMed Javanbakht MH, Djalali M, Daneshpazhooh M, et al. Evaluation of antioxidant enzyme activity and antioxidant capacity in patients with newly diagnosed pemphigus vulgaris. Clin Exp Dermatol. 2015;40(3):313–7.CrossRefPubMed
14.
Zurück zum Zitat Rezazadeh F, Moshaverinia M, Handjani F, Khoshkholgh F, Saki N, Heiran A. The evaluation of serum lipids profile in patients with pemphigus vulgaris: a case-control study. Malays J Med Sci. 2020;27(2):57–63.PubMedPubMedCentral Rezazadeh F, Moshaverinia M, Handjani F, Khoshkholgh F, Saki N, Heiran A. The evaluation of serum lipids profile in patients with pemphigus vulgaris: a case-control study. Malays J Med Sci. 2020;27(2):57–63.PubMedPubMedCentral
15.
Zurück zum Zitat Feliciani C, Cozzani E, Marzano AV, et al. Italian guidelines in pemphigus—adapted from the European Dermatology Forum (EDF) and European Academy of Dermatology and Venerology (EADV). G Ital Dermatol Venereol. 2018;153(5):599–608.CrossRefPubMed Feliciani C, Cozzani E, Marzano AV, et al. Italian guidelines in pemphigus—adapted from the European Dermatology Forum (EDF) and European Academy of Dermatology and Venerology (EADV). G Ital Dermatol Venereol. 2018;153(5):599–608.CrossRefPubMed
16.
Zurück zum Zitat Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts. J Am Acad Dermatol. 2020;82(3):575–85.CrossRefPubMed Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts. J Am Acad Dermatol. 2020;82(3):575–85.CrossRefPubMed
17.
Zurück zum Zitat Harman KE, Brown D, Exton LS, et al. British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017. Br J Dermatol. 2017;177(5):1170–201.CrossRefPubMed Harman KE, Brown D, Exton LS, et al. British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017. Br J Dermatol. 2017;177(5):1170–201.CrossRefPubMed
18.
Zurück zum Zitat Gupta J, Raval RC, Shah AN, et al. Low-dose rituximab as an adjuvant therapy in pemphigus. Indian J Dermatol Venereol Leprol. 2017;83(3):317–25.CrossRefPubMed Gupta J, Raval RC, Shah AN, et al. Low-dose rituximab as an adjuvant therapy in pemphigus. Indian J Dermatol Venereol Leprol. 2017;83(3):317–25.CrossRefPubMed
19.
Zurück zum Zitat Vinay K, Cazzaniga S, Amber KT, Feldmeyer L, Naldi L, Borradori L. Rituximab as first-line adjuvant therapy for pemphigus: retrospective analysis of long-term outcomes at a single center. J Am Acad Dermatol. 2018;78(4):806–8.CrossRefPubMed Vinay K, Cazzaniga S, Amber KT, Feldmeyer L, Naldi L, Borradori L. Rituximab as first-line adjuvant therapy for pemphigus: retrospective analysis of long-term outcomes at a single center. J Am Acad Dermatol. 2018;78(4):806–8.CrossRefPubMed
20.
Zurück zum Zitat Tavakolpour S, Mahmoudi H, Balighi K, Abedini R, Daneshpazhooh M. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review. Int Immunopharmacol. 2018;54:131–8.CrossRefPubMed Tavakolpour S, Mahmoudi H, Balighi K, Abedini R, Daneshpazhooh M. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review. Int Immunopharmacol. 2018;54:131–8.CrossRefPubMed
21.
Zurück zum Zitat Albers LN, Liu Y, Bo N, Swerlick RA, Feldman RJ. Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab. J Am Acad Dermatol. 2017;77(6):1074–82.CrossRefPubMed Albers LN, Liu Y, Bo N, Swerlick RA, Feldman RJ. Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab. J Am Acad Dermatol. 2017;77(6):1074–82.CrossRefPubMed
22.
Zurück zum Zitat Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol. 2008;128(12):2850–8.CrossRefPubMed Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol. 2008;128(12):2850–8.CrossRefPubMed
23.
Zurück zum Zitat Dermatology Branch of China International Exchange and Promotion Association for Medical and Healthcare. [Diagnosis and treatment of pemphigus vulgaris: an expert proposal]. Chin J Dermatol. 2020;53(1):1–7. Dermatology Branch of China International Exchange and Promotion Association for Medical and Healthcare. [Diagnosis and treatment of pemphigus vulgaris: an expert proposal]. Chin J Dermatol. 2020;53(1):1–7.
Metadaten
Titel
Assessment of anti-desmoglein antibodies levels and other laboratory indexes as objective comprehensive indicators of patients with pemphigus vulgaris of different severity: a single-center retrospective study
verfasst von
Xiaoying Lin
Xiaolan Li
Publikationsdatum
21.04.2022
Verlag
Springer International Publishing
Erschienen in
Clinical and Experimental Medicine / Ausgabe 2/2023
Print ISSN: 1591-8890
Elektronische ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-022-00823-2

Weitere Artikel der Ausgabe 2/2023

Clinical and Experimental Medicine 2/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.